Instructions for Simvastatin 30 pills
English product name
Simvastatin-VERTEX
Release Form
tab. film sheath, 10 mg: 15 or 30 pcs.
tab. film sheath, 20 mg: 15 or 30 pcs.
Description
The tablets are covered with a brown film shell and are round and double-convex; the cross-section core is white or almost white.
1 tab.
simvastatin 20 mg
Auxiliary substances:
lactose monohydrate - 138.46 mg, corn starch - 14 mg, cellulose microcrystalline 101 - 10 mg, ascorbic acid - 5 mg, hyprolosis (hydroxypropyl cellulose) - 4 mg, sodium croskarmellose - 4 mg, citric acid monohydrate - 2.5 mg, butyl hydroxyanisole - 0.04 mg, calcium stearate - 2 mg.
The film sheath consists of: [hypromellose - 4 mg, hyprolose (hydroxypropyl cellulose) - 1.552 mg, talc - 1.5408 mg, titanium dioxide - 0.088 mg, iron oxide black dye - 0.3232 mg, iron oxide red dye - 0.312 mg, iron oxide yellow dye - 0.184 mg] or [dry film coating mixture containing hypromellose (50%), hyprolose (hydroxypropyl cellulose) (19.4%) For example, talc (19.26%), titanium dioxide (1.1%), iron oxide black (4.04%), iron oxide red (3.9%), iron oxide yellow (2.3%)] - 8 mg.
ATC codes
C10AA01 Simvastatin
Clinical-pharmacological groups / Group affiliation
Hypolipidemic drug
Active substance
simvastatin
Pharmaco-therapeutic group
Hypolipidemic agent - reductase inhibitor GMG-CoA
Storage Conditions
In a dry, inaccessible place for children, protected from light at a temperature not higher than 25 ° C.
Best before date
Best before date -
two years.
Pharmacological effect Simvastatin
The hypolipidemic agent produced synthetically from the fermentation product Aspergillus terreus is an inactive lactone and undergoes hydrolysis in the body to form a hydroxy-acid derivative. The active metabolite inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase (GMG-CoA reductase), an enzyme that catalyzes the initial formation of mevalonate from GMG-CoA.
Testimony Simvastatin
Hypercholesterolaemia:
Primary hypercholesterolemia (type IIa and IIb) in the case of failure of low-cholesterol diet therapy and other non-medicamentous interventions (exercise and weight loss) in patients at higher risk of coronary atherosclerosis;
combined hypercholesterolemia and hypertriglyceridemia, not corrected by special diet and exercise.
Ischaemic heart disease:
for prevention of myocardial infarction, for reduction of risk of death, reduction of risk of cardiovascular disorders (stroke or transient ischemic attacks), slowing of progression of atherosclerosis of coronary vessels, reduction of risk of revascularization procedures.
Method of use, course and dosage
Prior to Simvastatin treatment, the patient should be prescribed a standard hypocholesterolaemia diet, which should be followed throughout the course of treatment.
Simvastatin should be taken in 1 time/day in the evening, drinking enough water. The time of taking the drug should not be associated with eating.
The recommended dose of Simvastatin for the treatment of hypercholesterolemia ranges from ten to 80 mg once a day in the evening.
The recommended initial dose for patients with hypercholesterolemia is ten mg. The maximum daily dose is 80 mg.
Use in children
It is contraindicated for children under 18 years of age.
- Nosology (ICD codes)
- E78.0
- Pure hypercholesterolemia
- E78.2
- Mixed hyperlipidemia
- G45
- Transitory cerebral ischemic attacks [attacks] and related syndromes
- I21
- Acute myocardial infarction
- I25.1
- Atherosclerotic heart disease
- I63
- Brain infarction